Drugs / [C-11]PBR28
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00547976 | Oct 2007 → Aug 2009 | atherosclerosis | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 1 | NCT00526916 | Sep 2007 → Sep 2014 | cysticercosis | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02649985 | May 2016 → Dec 2027 expected | Alzheimer disease, multiple sclerosis | Brigham and Women's Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [C-11]PBR28 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00547976 ↗ |
| Known as | [11C]PBR28 | “Translocator protein 18 kDa (TSPO) has been widely imaged as a marker of neuroinflammation using several radioligands, including [11C]PBR28.” PMID 29749279 ↗ May 20181“the 18 kDa translocator protein (TSPO) tracers [11C]-PBR28 and [18F]-PBR06 for imaging inflammatory vascular disease in vitro and in vivo.” PMID 33950298 ↗ May 2021 |
| Known as | PBR28 | “Recently we developed a new ligand, \[(11)C\]N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine (PBR28), which showed much greater specific signal than \[(11)C\]PK11195 in...” NCT00526916 ↗ |
| Modality | Diagnostic / imaging agent | “Translocator protein 18 kDa (TSPO) has been widely imaged as a marker of neuroinflammation using several radioligands, including [11C]PBR28.” PMID 29749279 ↗ May 2018 |
| Target | TSPO | “the 18 kDa translocator protein (TSPO) tracers [11C]-PBR28 and [18F]-PBR06” PMID 33950298 ↗ May 2021 |